Advancing RNA Therapy with Higher Confidence
Bringing human biology into the discovery of RNA therapeutics can be
easily achieved by using the iPSC-based Ncardia platform
We help you select the most promising RNA therapeutic candidate earlier with our robust iPSC-platform
The potential of RNA therapeutics, such as small interfering RNA (siRNA), messenger RNA (mRNA), antisense oligonucleotides (ASOs), and microRNA (miRNA), can be hindered by low specificity, risk of off-target effects, challenging delivery or limited clinical translation.
Human induced pluripotent stem cell (iPSC) technology offers a powerful platform for addressing those key challenges by bringing in translational disease models and screening assays. Additionally, iPSC-derived cells can be patient-specific, a key aspect to success in the development of therapies for rare diseases.
Benefits of Ncardia Solutions
We facilitate your decision-making steps during the selection of RNA therapeutics by integrating human models and clinically relevant readouts
![](https://www.ncardia.com/hs-fs/hubfs/Icons/0104%20NCARDIA%20BENEFIT%20ICONS-2_modeling%20-%20high%20reproducibility.png?width=150&height=150&name=0104%20NCARDIA%20BENEFIT%20ICONS-2_modeling%20-%20high%20reproducibility.png)
High Reproducibility
Consistent results with our optimized assays
![](https://www.ncardia.com/hs-fs/hubfs/Icons/0104%20NCARDIA%20BENEFIT%20ICONS-2_modeling%20-%20relevant%20human%20biology.png?width=150&height=150&name=0104%20NCARDIA%20BENEFIT%20ICONS-2_modeling%20-%20relevant%20human%20biology.png)
Predictive Responses
Testing on relevant
human biology
![](https://www.ncardia.com/hs-fs/hubfs/Icons/0104%20NCARDIA%20BENEFIT%20ICONS-2_Time.png?width=150&height=150&name=0104%20NCARDIA%20BENEFIT%20ICONS-2_Time.png)
Quick Turnaround
A team focused on timely delivery of reliable data
What we can do for you
We harness our expertise in human biology and iPSC technology to offer robust miniaturized assays for:
- Optimize delivery strategies
- Enhance cellular uptake
- Assess early pharmacology and predict efficacy
- Minimize the chances of late-stage toxicity
Whether you opt for our ready-to-use assays or require a custom solution, our expert team is ready to assist you.
![ASO screening ASO screening](https://www.ncardia.com/hubfs/ASO%20screening.png)
Download this poster to learn more about our iPSC platform for RNA therapeutics
Related topics
![](https://www.ncardia.com/hubfs/Antisense%20blog%20graphic%20v2@3x.png)
![](https://www.ncardia.com/hubfs/Expert%20insights%20%282%29.png)
![](https://www.ncardia.com/hubfs/Ncardia-17.jpeg)
Contact Us
If you're ready to explore how to accelerate the discovery of RNA therapeutics with a leading iPSC-based platform, we'd welcome the opportunity to introduce you to Ncardia.
![Asha 2](https://www.ncardia.com/hubfs/Asha%202.png?noresize)